1
|
Harkensee C, Oka A, Onizuka M, Middleton PG, Inoko H, Nakaoka H, Gennery AR, Ando K, Morishima Y. Microsatellite scanning of the immunogenome associates MAPK14 and ELTD1 with graft-versus-host disease in hematopoietic stem cell transplantation. Immunogenetics 2013; 65:417-27. [PMID: 23474535 DOI: 10.1007/s00251-013-0691-z] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2012] [Accepted: 02/16/2013] [Indexed: 12/16/2022]
Abstract
Graft-versus-host disease (GVHD) is the main complication after hematopoietic stem cell transplantation (HSCT). Evidence for non-HLA gene polymorphisms as a cause of GVHD lacks consistency, which is, in part, due to methodological issues of previous candidate gene association studies and small effect size of their results, demanding for larger scale and more robust approaches. Here, non-HLA gene polymorphisms were studied on a large population (922 HSCT pairs) from a homogeneous ethnic background with selection/correction for important clinical confounders. A methodology was applied exploiting the strength of confirmatory typing in an independent study cohort. Targeting an immunogenome of 2,909 genes, an approach of pooled DNA typing of 4,321 microsatellite (MS) markers in two independent screening steps and confirmation of associated markers by further individual genotyping on combined screening cohorts was used to identify genetic susceptibility loci for moderate to severe GVHD (grades 2-4). Ten MS loci (D5S424, D6S0035i, D1S0818i, DXS0151i, D17S0219i, DXS0629i, DXS0324i, D17S0271i, D6S0330i, and D1S1335i) passed the two pooled DNA typing steps and confirmation by individual sample genotyping; two of these (D1S0818i-ELTD1 and D6S0035i-MAPK14) remain associated following application of Bonferroni's correction and multivariate analysis. The MAPK14 locus was exemplarily explored by typing of haplotype single nucleotide polymorphisms (SNP) confirming this association. This study identified several new MS susceptibility loci for GVHD that warrant further investigation. Immunogenome scanning using MS markers is a useful method for the identification of non-HLA gene loci associating with HSCT outcomes.
Collapse
Affiliation(s)
- Christian Harkensee
- Division of Molecular Life Sciences, Tokai University School of Medicine, Isehara, Kanagawa, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Tiercy JM. Immunogenetics of hematopoietic stem cell transplantation: the contribution of microsatellite polymorphism studies. Int J Immunogenet 2011; 38:365-72. [PMID: 21816003 DOI: 10.1111/j.1744-313x.2011.01026.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Polymorphisms of short tandem repeats of <10 nucleotides, or microsatellites (Msat), are largely used for post-transplant chimerism analyses in clinical hematopoietic stem cell transplantation (HSCT). Compared to single nucleotide polymorphisms (SNP), they have the advantage of a higher degree of allelic polymorphism and thus a potentially larger degree of informativity. Msat markers contribute to approximately 3% of the human genome and have been highly informative in disease association studies, population genetics, forensic medicine and organ and HSC transplantation. They allowed to expand our knowledge of the haplotypic structure of the HLA complex, including the noncoding sequences in the MHC, and to reach a better characterization of immunological phenotypes. Among the different immunogenetic studies in HSCT patients reviewed here, four Msat loci linked to cytokine genes have been analysed by a number of laboratories as potential candidates markers for HSCT outcome: IFNG, TNFd, IL-10(-1064) and IL-1RN. The low patient numbers and high diversity of clinical parameters account for some heterogeneity of the results. Among the trends starting to emerge from these studies, specific TNFd Msat alleles seem to be associated with acute graft-versus-host disease and mortality. Patient/donor Msat incompatibilities have also been used as surrogate markers to map biologically relevant polymorphisms, with a main focus on MHC-resident genetic variation. High throughput SNP typing and next-generation sequencing technologies will allow acquisition of large-scale genomic data and should allow refined analyses of clinically relevant genotypes in the transplantation settting, although the heterogeneity of the study cohorts will remain an issue. The analysis of Msat polymorphisms may still have a place in functional studies on the impact of Msat diversity in the control of immune response gene expression.
Collapse
Affiliation(s)
- J-M Tiercy
- National Reference Laboratory for Histocompatibility, Department of Internal Medicine, University Hospital Geneva, Geneva, Switzerland.
| |
Collapse
|
3
|
Turpeinen H, Volin L, Nikkinen L, Ojala P, Palotie A, Saarela J, Partanen J. Genetic similarity of chromosome 6 between patients receiving hematopoietic stem cell transplantation and HLA matched sibling donors. Haematologica 2009; 94:528-35. [PMID: 19278967 DOI: 10.3324/haematol.2008.000919] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
BACKGROUND Matching for HLA genes located on chromosome 6 is required in hematopoietic stem cell transplantation to reduce the incidence of graft-versus-host disease. However, a considerable proportion of patients still suffer from it, obviously due to genetic differences outside the HLA gene region. DESIGN AND METHODS We studied the similarity of almost 4,000 single nucleotide polymorphisms on chromosome 6 between patients receiving hematopoietic stem cell transplantation and their HLA-matched sibling donors. RESULTS We observed that as a result of routine HLA matching the siblings in fact shared surprisingly long chromosomal fragments with similar single nucleotide polymorphism genotypes--from 11.65 Mb to 134.66 Mb. The number of genes mapped on these shared fragments varied from 402 to 1,302. Considering the whole chromosome 6, the HLA-matched siblings were apparently identical for 65.2-97.8% of the single nucleotide polymorphisms. CONCLUSIONS Potentially, genes similar in some transplantation pairs while different in others might have a significant role in determining the outcome after hematopoietic stem cell transplantation.
Collapse
Affiliation(s)
- Hannu Turpeinen
- Finnish Red Cross Blood Service, Kivihaantie 7, 00310 Helsinki, Finland.
| | | | | | | | | | | | | |
Collapse
|
4
|
Markiewicz M, Siekiera U, Karolczyk A, Szymszal J, Helbig G, Wojnar J, Dzierzak-Mietla M, Kyrcz-Krzemien S. Immunogenic disparities of 11 minor histocompatibility antigens (mHAs) in HLA-matched unrelated allogeneic hematopoietic SCT. Bone Marrow Transplant 2008; 43:293-300. [PMID: 18850018 DOI: 10.1038/bmt.2008.326] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
We determined the alleles of 11 mHAs and investigated the association of immunogenic mHA mismatches between a donor and a recipient with a course of allogeneic hematopoietic SCT (allo-HSCT) from 10/10 alleles HLA-matched unrelated donors in 92 recipients after myeloablative conditioning between 2004 and 2006. The frequency analysis of mHA alleles, genotypes and phenotypes accompanied by appropriate restriction HLA Ags allowed for an estimation of the probability of immunogenic mismatches, which was the highest for HA-1, HA-8 and HY. GVH-directed disparity of mHAs with broad tissue distribution, especially of the sex-related HY Ag, influenced the results of allo-HSCT from HLA-matched unrelated donors by not only increasing the probability of chronic GVHD (cGVHD) but also by decreasing the relapse rate.
Collapse
Affiliation(s)
- M Markiewicz
- Department of Hematology and Bone Marrow Transplantation, Medical University of Silesia, Dabrowskiego 25, Katowice, Poland.
| | | | | | | | | | | | | | | |
Collapse
|
6
|
Malkki M, Gooley TA, Horowitz MM, Absi L, Christiansen FT, Cornelissen JJ, Dormoy A, Dubois V, Gagne K, Gluckman E, Haagenson MD, Oudshoorn M, Spellman S, Petersdorf EW. Mapping MHC-resident transplantation determinants. Biol Blood Marrow Transplant 2007; 13:986-95. [PMID: 17640603 PMCID: PMC3182140 DOI: 10.1016/j.bbmt.2007.05.007] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2007] [Accepted: 05/08/2007] [Indexed: 01/02/2023]
Abstract
Graft-versus-host disease (GVHD) accounts for increased morbidity and mortality after HLA-identical unrelated hematopoietic cell transplantation (HCT). To test the hypothesis that the major histocompatibility complex (MHC) encodes functional variation other than the classical HLA genes, we measured risks associated with donor-recipient MHC microsatellite (Msat) marker mismatching in 819 HCT recipients and their HLA-A, -B, -C, -DRB1, and -DQB1 allele-matched unrelated donors. Suggestive trends of association with transplant outcome were observed for 5 Msats. Donor-recipient mismatching for the extended class I D6S105, class III D6S2787, and class II D6S2749 markers was each associated with an increased risk of death (hazard ratio, 1.32; 95% confidence interval, 1.02-1.71; P=.03; hazard ratio, 1.26; 95% confidence interval, 1.03-1.53; P=.02; hazard ratio, 1.37; 95% confidence interval, 1.08-1.72; P=.007, respectively) whereas mismatching for the class I D6S2811 marker was associated with a decreased risk of death (hazard ratio, 0.80; 95% confidence interval, 0.66-0.98; P=.03). Mismatching for the class I D6S265 marker was associated with a decreased risk of grades III-IV acute GVHD (odds ratio, 0.67; 95% confidence interval, 0.45-0.98; P=.04). These results suggest that Msats may be informative for mapping MHC-resident genetic variation of clinical importance in HCT.
Collapse
Affiliation(s)
- Mari Malkki
- The Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - Ted A. Gooley
- The Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - Mary M. Horowitz
- Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI, USA
| | - Lena Absi
- Laboratoire HLA, EFS Auvergne Loire, St. Etienne, France
| | - Frank T. Christiansen
- Department of Clinical Immunology and Immunogenetics, PathWest and Royal Perth Hospital, Perth, Australia
| | - Jan J. Cornelissen
- Department of Hematology, Erasmus University Medical Center- Daniel Den Hoed, Rotterdam, The Netherlands
| | - Anne Dormoy
- Laboratoire d'Histocompatibilité, Etablissement Français du Sang-Alsace, Strasbourg, France
| | - Valerie Dubois
- Laboratoire d'Histocompatibilité, EFS Rhone Alpes, Lyon, France
| | - Katia Gagne
- Laboratoire d'Histocompatibilité et d'Immunogénétique, EFS Pays de Loire, Nantes, France
| | | | - Michael D. Haagenson
- Center for International Blood and Marrow Transplant Research, Minneapolis, MN, USA
| | | | | | - Effie W. Petersdorf
- The Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
- The Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA
| | | |
Collapse
|